JPWO2021145435A1 - - Google Patents
Info
- Publication number
- JPWO2021145435A1 JPWO2021145435A1 JP2021571266A JP2021571266A JPWO2021145435A1 JP WO2021145435 A1 JPWO2021145435 A1 JP WO2021145435A1 JP 2021571266 A JP2021571266 A JP 2021571266A JP 2021571266 A JP2021571266 A JP 2021571266A JP WO2021145435 A1 JPWO2021145435 A1 JP WO2021145435A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020004403 | 2020-01-15 | ||
| PCT/JP2021/001276 WO2021145435A1 (ja) | 2020-01-15 | 2021-01-15 | 認知症の予防又は治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2021145435A1 true JPWO2021145435A1 (US07682611-20100323-C00002.png) | 2021-07-22 |
| JPWO2021145435A5 JPWO2021145435A5 (US07682611-20100323-C00002.png) | 2024-01-22 |
Family
ID=76863789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571266A Pending JPWO2021145435A1 (US07682611-20100323-C00002.png) | 2020-01-15 | 2021-01-15 |
Country Status (13)
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| CA2140638C (en) | 1992-07-24 | 2010-05-04 | Raju Kucherlapati | Generation of xenogeneic antibodies |
| CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
| CA2785941C (en) | 2000-10-06 | 2017-01-10 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| WO2005035586A1 (ja) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | 融合蛋白質組成物 |
| JP3981148B2 (ja) | 2004-03-11 | 2007-09-26 | バイオクルーズ株式会社 | 軸索再生促進剤 |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| IL305223A (en) | 2012-01-27 | 2023-10-01 | Abbvie Inc | The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells |
| EP3584260A1 (en) * | 2015-04-28 | 2019-12-25 | Mitsubishi Tanabe Pharma Corporation | Rgma binding protein and use thereof |
-
2021
- 2021-01-15 EP EP21741964.7A patent/EP4091633A1/en active Pending
- 2021-01-15 CN CN202180009256.7A patent/CN114945385A/zh active Pending
- 2021-01-15 AR ARP210100097A patent/AR121065A1/es unknown
- 2021-01-15 AU AU2021207010A patent/AU2021207010A1/en active Pending
- 2021-01-15 IL IL294769A patent/IL294769A/en unknown
- 2021-01-15 JP JP2021571266A patent/JPWO2021145435A1/ja active Pending
- 2021-01-15 MX MX2022008588A patent/MX2022008588A/es unknown
- 2021-01-15 CA CA3168209A patent/CA3168209A1/en active Pending
- 2021-01-15 US US17/792,574 patent/US20230090965A1/en active Pending
- 2021-01-15 TW TW110101615A patent/TW202140555A/zh unknown
- 2021-01-15 BR BR112022013944A patent/BR112022013944A2/pt unknown
- 2021-01-15 KR KR1020227024169A patent/KR20220113794A/ko active Search and Examination
- 2021-01-15 WO PCT/JP2021/001276 patent/WO2021145435A1/ja unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021145435A1 (ja) | 2021-07-22 |
| EP4091633A1 (en) | 2022-11-23 |
| KR20220113794A (ko) | 2022-08-16 |
| TW202140555A (zh) | 2021-11-01 |
| BR112022013944A2 (pt) | 2022-09-20 |
| CN114945385A (zh) | 2022-08-26 |
| US20230090965A1 (en) | 2023-03-23 |
| AU2021207010A1 (en) | 2022-08-25 |
| IL294769A (en) | 2022-09-01 |
| MX2022008588A (es) | 2022-08-10 |
| CA3168209A1 (en) | 2021-07-22 |
| AR121065A1 (es) | 2022-04-13 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240112 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240112 |